Skip to main content

Medicenna Therapeutics Corp(MDNA-T)
TSX

Today's Change
Real-Time Last Update
Day Low1.11
Day High1.20
Open:1.18
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
GlobeNewswire
Medicenna Announces Appointment of New Auditor
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab
GlobeNewswire
Medicenna Extends Period to Exercise Certain Warrants
GlobeNewswire
Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncology
GlobeNewswire
Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights
GlobeNewswire
Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting
GlobeNewswire
Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
GlobeNewswire
Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna Announces Nasdaq Delisting and Cutback of Management Team
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors
GlobeNewswire
Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer
GlobeNewswire
Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy
GlobeNewswire
Medicenna Announces Results of Annual and Special Meeting of Shareholders
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

Profile

Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.